{"id":1054,"date":"2001-02-01T12:04:00","date_gmt":"2001-02-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/kosten-nutzen-analyse-von-interferon-beta-1b-bei-multipler-sklerose"},"modified":"2001-02-01T12:04:00","modified_gmt":"2001-02-01T11:04:00","slug":"kosten-nutzen-analyse-von-interferon-beta-1b-bei-multipler-sklerose","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/kosten-nutzen-analyse-von-interferon-beta-1b-bei-multipler-sklerose","title":{"rendered":"Kosten-Nutzen-Analyse von Interferon beta-1b bei Multipler Sklerose"},"content":{"rendered":"<p>Dr. E.S. aus B. schreibt (gek\u00fcrzt): >> Das Referat (AMB 2000, 34, 23b) bezieht sich auf eine Publikation von R.B. Forbes et al. (Brit. Med. J.1999, 319, 1529). Die Autoren folgerten, da\u00df die Behandlung der sekund\u00e4r progredienten Multiplen Sklerose mit Interferon beta-1b (INF beta-1b) wegen der hohen Kosten und der geringen klinischen Effekte nicht sinnvoll [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. E.S. aus B. schreibt (gek\u00fcrzt): >> Das Referat (AMB 2000, 34, 23b) bezieht sich auf eine Publikation von R.B. Forbes et al. (Brit. Med. J.1999, 319, 1529). Die Autoren folgerten, da\u00df die Behandlung der sekund\u00e4r progredienten Multiplen Sklerose mit Interferon beta-1b (INF beta-1b) wegen der hohen Kosten und der geringen klinischen Effekte nicht sinnvoll [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2113,352],"class_list":["post-1054","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-interferon-beta-1b","tag-multiple-sklerose"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1054"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1054\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}